Business Wire

Eyenuk, Inc. Expands into Germany with Launch of EyeArt® Artificial Intelligence Eye Screening for Diabetic Retinopathy

Share

Eyenuk, Inc. announces its expansion into Germany with the adoption of EyeArt® artificial intelligence (AI) technology for the screening of diabetic retinopathy at Diabetes Center Mergentheim in Bad Mergentheim, Germany. The center is the first dedicated diabetic clinic in Germany to use artificial intelligence for screening of diabetic retinopathy, the leading cause of vision loss in working-age adults(1).

The EyeArt system utilizes artificial intelligence and Deep Learning to autonomously read retinal images and screen for diabetic retinopathy in under 60 seconds. It is estimated that one-third of all patients with diabetes will develop the blinding-eye disease(2), and that the worldwide incidence of diabetic retinopathy will rise to 191 million people by 2030(3). In Germany, diabetic retinopathy causes nearly 2,000 new cases of blindness each year(4). Eyenuk is committed to deploy its EyeArt system globally and aims to eliminate instances of preventable blindness.

“We are gratified to see the global adoption for the EyeArt system and the opportunity that the technology offers to primary care and diabetes clinics,” said Kaushal Solanki, president and CEO of Eyenuk. “The EyeArt system will enable millions of patients to be screened in real time for early disease detection, and be expeditiously identified for referral to a vision specialist.”

The vast majority of patients with diabetes who develop diabetic retinopathy have no symptoms until damage to their vision is irreversible. While annual ophthalmic screening is recommended for all those with diabetes, even in the developed world, typically less than half get screened. Adding to this is the limited number of ophthalmologists, healthcare providers with a retinal (fundus) camera, and a historical delay in ophthalmologist appointments for screening or remote image reading.

“Until now, we’ve had to encourage our patients to see an ophthalmologist for annual diabetic retinopathy screening,” said Professor Dr. med. Thomas Haak, medical director, Diabetes Center Bad Mergentheim. “However, because the disease shows no symptoms until it’s nearly too late, many are putting off that screening visit. Now with the EyeArt system deployed in our clinic, we can directly screen our diabetes patients on-site for this blinding disease, and possibly save the vision of many who otherwise would have gone undetected.”

ABOUT THE EYEART SYSTEM

The EyeArt system has received a CE marking in the European Union and a Medical Device License from Health Canada.

The EyeArt system utilizes artificial intelligence and deep learning to rapidly and autonomously review images taken of a patient’s retina by the provider’s own choice of fundus camera. During the patient’s visit, retinal images are analyzed by the secure HIPAA-compliant cloud-based EyeArt system, and within 60 seconds, the physician is sent a screening report for referable and vision-threatening diabetic retinopathy.

VIDEO: See How the EyeArt System Performs Eye Screening for Diabetic Retinopathy

The EyeArt system has been validated on one of the largest data sets of patient cases of any available diabetic retinopathy screening technology, in demanding, real-world settings using images captured in everyday practice. In a clinical study of over 100,000 consecutive patient visits from the EyePACS Telescreening Program, the EyeArt system (version 2.0) was found to have a sensitivity and specificity rate of over 91% in identifying patients with referable diabetic retinopathy(5).

The reporting, which uses internationally recognized standards, such as the UK’s NHS Diabetic Eye Screening Programme (NDESP) and the International Clinical Diabetic Retinopathy Disease Severity Scale (ICDR), indicates whether any diabetic retinopathy, referable retinopathy, or vision-threatening retinopathy is detected. Additionally, the level of retinopathy on ICDR or NDESP scale is also reported for each eye.

In the United States, the EyeArt system is limited by federal law to investigational use only and is not available for sale.

ABOUT EYENUK, INC.

Eyenuk, Inc., headquartered in Los Angeles, California, is an AI diagnostic company focused on quickly and accurately identifying patients suffering from potentially blinding eye diseases and chronic diseases at the point of care. Using computer vision and artificial intelligence expertise, the company is developing a portfolio of products based on its proprietary retinal image analysis technology combined with deep learning to identify and track the progression of diseases including diabetic retinopathy, glaucoma, age-related macular degeneration, risk of stroke, cardiovascular risk, and Alzheimer’s disease.

EyeArt is a registered trademark of Eyenuk, Inc.

www.eyenuk.com
https://www.youtube.com/channel/UClpK-To5-z5cQIFpSbACprA
https://www.linkedin.com/company/eyenuk-llc/

_____________________________________
1.Prokofyeva E, Zrenner E. Epidemiology of major eye diseases leading to blindness in Europe: a literature review. Ophthalmic Res. 2012;47:171–188.
2.Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35:556–64.
3.International Diabetes Federation. Diabetes atlas, 6th ed, Brussels, Belgium. 2015.
4.DIabetesDE.org. Accessed Oct. 1, 2018.
5.Solanki et al., “Validation of EyeArt Automated Diabetic Retinopathy Screening System on large cohort of mydriatic and non-mydriatic telescreening data from EyePACS.” ARVO 2017, Baltimore, MD.

Contact information

Capwell Communications
Ramune Carothers, 949-999-3303
ramune@capwellcomm.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

New data show first-line triplet regimen of pembrolizumab, Herzuma ® (biosimilar trastuzumab) and chemotherapy are effective in treatment of HER2-positive advanced gastric cancer29.5.2020 01:01:00 CESTPress release

Data presented today as part of the ASCO20 Virtual Scientific Program show that a first-line triplet regimen comprising of pembrolizumab, Herzuma®(biosimilar trastuzumab) and chemotherapy is effective in patients with HER2-positive advanced gastric cancer (AGC). The PANTHERA trial (a phase Ib/II study of first line pembrolizumab in combination with trastuzumab, capecitabine, and cisplatin in HER2-positive gastric cancer), sponsored by Celltrion Inc. and MSD, is investigating the potential of a first-line immunotherapy/chemotherapy combination with biosimilar trastuzumab. This is in light of a growing body of evidence that the immune system contributes to the therapeutic effects of monoclonal antibodies such as biosimilar trastuzumab in treating solid tumours.1 A total of 43 patients were treated with a median follow up of 18 months. Patients were treated with pembrolizumab 200mg via IV infusion D1,biosimilar trastuzumab 6mg/kg (after 8mg/kg load) D1, capecitabine 1000mg/m2 bid D1-D14 a

European Commission Releases Takeda From Commitment to Divest Shire’s Pipeline Compound SHP64729.5.2020 01:00:00 CESTPress release

Takeda Pharmaceutical Company Limited (TOKYO:4502) (NYSE:TAK) (“Takeda”) today announces that on May 28, the European Commission (the “EC”) has released Takeda from the obligation to divest the pipeline compound SHP647 and certain associated rights (“SHP647”), a commitment that was provided by Takeda to secure regulatory clearance of its acquisition of Shire plc (“Shire”). Takeda will discontinue the current SHP647 clinical trial program, and it will be providing all eligible trial participants with the opportunity to have continued access to SHP647 in a post-trial access (“PTA”) study. In addition, subject to obtaining trial participant consents and the satisfaction of regulatory and ethical considerations, Takeda will make SHP647 clinical trial data and biosamples available to the scientific community through the Crohn’s & Colitis Foundation (“Foundation”). Takeda announced on November 20, 2018, that the EC approved its proposed acquisition of Shire (the “Acquisition”). The EC’s appr

Jefferies' Clients, Employees and Shareholders Contribute $9,250,000 to Over 85 Charities for Coronavirus Relief in Memory of Peg Broadbent28.5.2020 18:02:00 CESTPress release

Jefferies announced today a total donation to over 85 different charities of $9.25 million as a result of a firmwide global effort to raise money to honor the memory of their late CFO Peg Broadbent, who was a victim of this terrible disease. Through the firm’s Global Coronavirus Relief Charity Day held May 27th, Jefferies’ clients helped to generate $7.65 million in donated net trading commissions. In addition, Jefferies as a firm will donate $1 million directly, and voluntary donations from Jefferies’ 3,822 employees totaled $600,000. “We could not be prouder of our entire Jefferies family for raising $9.25 million and are greatly appreciative of the incredible partnership our clients have shown us in supporting our fight against Covid-19. The full $9.25 million will be wired today and go to direct relief efforts at over 85 worthy global charities who are each in the front lines helping those most impacted by the Coronavirus global pandemic. We went broadly to a large number of charit

JRJ Group Announces Sale of ETX Capital to Guru Capital28.5.2020 15:30:00 CESTPress release

JRJ Group, a leading international private equity investment firm focused on the financial services sector and growth situations, is pleased to announce that it has agreed to terms for the sale of ETX Capital, one of the fastest growing international providers of multi-asset CFDs and spread betting products, to a fund associated with Guru Capital, a Switzerland-based private equity firm with specific experience in the CFD space. Terms of the transaction were not disclosed. Roger Nagioff, Founding Partner of JRJ Group, said, “During JRJ’s ownership, we have invested in bolt-on acquisitions and enhanced the technology of the firm. We are delighted with the strength and resilience of the platform we have built, alongside the management team and employees, and we wish the enterprise every success in its next stage of growth.” “We are grateful of JRJ Group’s support, and we look forward to growing the business with the Guru Capital team, who have substantial experience in the CFD sector,” s

eLichens Launches eStore for US and EU Markets28.5.2020 15:00:00 CESTPress release

French start-up eLichens has launched its online store last week. eLos, for eLichens Outdoor Station, can now be purchased online by US and EU customers. Japan and other areas will soon join the list. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200528005117/en/ (Photo: Business Wire) eLos is a wireless, solar-powered air quality station. eLos provides citizens, communities and organizations the most accurate and complete real-time data about air quality, wherever they need it. Visit the store and learn more about eLos : https://www.elichens.com/store/elos View source version on businesswire.com: https://www.businesswire.com/news/home/20200528005117/en/Contact information Marc Attia, press@elichens.com

SAB Biotherapeutics Confirms Neutralizing Antibodies to SARS-CoV-2 and Begins Clinical Manufacturing of Novel COVID-19 Therapeutic Candidate28.5.2020 14:24:00 CESTPress release

SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a proprietary technology to produce fully human polyclonal antibodies without the need for human plasma donors, today announced in vitro data demonstrating that SAB-185, its COVID-19 therapeutic candidate, has highly-potent neutralizing antibodies to SARS-CoV-2 that are four times higher than the most potent human convalescent plasma serum sample evaluated. The company also announced that they initiated manufacturing of SAB-185 on May 25 to support the next phase of clinical development for its potential COVID-19 therapeutic, still on track to begin human trials in early summer. “These data indicate this human polyclonal antibody therapeutic has potent neutralizing activity against live SARS-CoV-2. The neutralizing titers of SAB-185 are significantly higher than those of the most potent plasma of recovered COVID-19 patients we’ve been able to source,” said William B. Klimstra, PhD Associate Professor of Microbio